Merck KGaA's Erbitux beats Avastin in bowel cancer trial

[riky]

Merck KGaA's Erbitux beats Avastin in bowel cancer trial

FRANKFURT (Reuters) - Merck KGaA's cancer drug Erbitux was shown to be more effective at prolonging the lives of bowel cancer patients than Roche's Avastin, Merck said. In a drug trial, the two drugs were each given in combination with Folfiri chemotherapy to patients whose colorectal cancer had started spreading to other organs. The results showed the Erbitux group survived on average nearly four months longer than the Avastin group. The trial was conducted by an independent research collaborative of the German Association of Medical Oncology (AIO) and sponsored by Germany's Merck. ...

Source: You are not allowed to view links. Register or Login